Test Price
2,800 AED✅ Home Collection Available
KCNQ1 Gene Atrial Fibrillation Type 3 Genetic Test in UAE
Executive Summary & Core Metrics
Executive Summary: Comprehensive genetic screening for hereditary atrial fibrillation type 3 via KCNQ1 gene sequencing. Achieves 99.9% diagnostic sensitivity using next-generation sequencing (NGS) under ISO 9001:2015 accreditation. Includes VIP mobile phlebotomy with temperature-controlled cold-chain home collection, telephonic post-test genetic counselling, and direct insurance billing verification via WhatsApp at +971 54 548 8731.
- Accuracy Guarantee: 99.9% diagnostic sensitivity via ISO-accredited processing.
- Premium Logistics: Hospital-grade home collection via ISO-certified cold-chain & VIP mobile phlebotomy — available daily from 8 AM to 11 PM.
- Clinical Guidance: Telephonic post-test genetic counselling included for result interpretation.
- Insurance: Direct billing verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
This advanced genetic test sequences the KCNQ1 gene using next-generation sequencing (NGS) on the Illumina platform to identify pathogenic variants responsible for familial atrial fibrillation type 3. Full-gene coverage exceeds 99.9%, enabling early risk stratification and personalised management.
| Feature | Our NGS Test | Closest Alternative |
|---|---|---|
| Precision | 99.9% full-gene coverage (NGS) | Limited single-gene Sanger panels |
| Methodology | Next-Generation Sequencing (NGS) – Illumina platform | PCR-based fragment analysis / older platforms |
| Turnaround Time | 3–4 weeks | 4–6 weeks (external referral) |
| Post-test Genetic Counselling | Included (telephonic) | Often not included |
Physician Insight & Safety Protocols
Lina Osama Zaki Quteineh (Consultant Medical Genetics, DHA: 9294403): “Detecting a KCNQ1 mutation can unlock life-saving rhythm control strategies, but a positive result must be interpreted within the full clinical picture—family history, ECG patterns, and symptom burden remain essential. I encourage every patient to share these results with their electrophysiologist or cardiologist for a personalised care plan.”
Advisory – Medication Warning
Do not discontinue prescribed medication (e.g., antiarrhythmics, anticoagulants) without consulting your doctor.
Exclusion Criteria & ER Red Flags
- Active haemodynamic instability or acute coronary syndrome – seek immediate emergency care, not a genetic test.
- Known pregnancy is not a contraindication, but postpone testing if medically unnecessary during an acute episode.
- Minors require a legal guardian’s consent (compliant with Federal Decree‑Law No. 4 of 2016 on Medical Liability).
- ER Red Flags: Sudden loss of consciousness, severe chest pain with palpitations, or signs of stroke – call 998 immediately.
Patient FAQ & Clinical Guidance
1. How accurate is the KCNQ1 gene test for atrial fibrillation type 3?
Our NGS-based test achieves >99.9% analytical sensitivity and specificity for detecting clinically significant KCNQ1 variants when performed on high-quality DNA samples. All results are confirmed through bidirectional sequencing and bioinformatics pipelines aligned with international guidelines.
2. How long does it take to get results?
Results are typically available within 3 to 4 weeks after sample receipt in the laboratory. Expedited processing may be arranged for urgent clinical cases after direct communication with our medical team via WhatsApp.
3. Is a KCNQ1 mutation always associated with atrial fibrillation, and what if my result is negative?
Not all KCNQ1 variants are pathogenic; a negative result does not exclude other genetic or acquired causes of atrial fibrillation. Clinical follow‑up with an electrophysiologist remains essential for comprehensive risk assessment and arrhythmia management.
UAE Regulatory & Data Privacy Adherence
- Testing adheres to Federal Decree‑Law No. 4 of 2016 on Medical Liability (genetic testing regulations).
- Minor consent governed by Federal Decree‑Law No. 4 of 2016 – a legal guardian’s approval is mandatory for patients under 18.
- Data privacy compliance with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.
- ISO 9001:2015 Certified Facility (Cert: INT/EGQ/2509DA/3139) – ensuring worldwide laboratory quality standards.
Clinical & Logistical Metadata
| Test Name | KCNQ1 Gene Atrial Fibrillation Type 3 Genetic Test |
| Price (AED) | 2,800 |
| Turnaround Time | 3–4 weeks |
| Sample Type / Matrix | Whole Blood (EDTA), Extracted DNA, or FTA card |
| Methodology Used | Next-Generation Sequencing (NGS) – Illumina platform |
| ICD-10-CM Code | Z13.6 (Encounter for screening for genetic and chromosomal anomalies) |
| LOINC Code | 80305-0 (Gene mutations found in KCNQ1 gene in Blood or Tissue by Sequencing) |
| DHA Facility License & Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians